US Electroceuticals Market Size | COVID-19 Impact Analysis | Forecast to 2025

US electroceuticals market is expected to grow at a CAGR of 7.8% during the forecast period. The market growth is attributed to the rise in the prevalence of arrhythmia, growing number of neural disorders, and high prevalence of hearing loss. In addition, rising number of Parkinson’s disease and expected approvals for retinal implants in the US are anticipated to contribute significantly to the growth of electroceuticals market. The US has a high incidence and prevalence rate of heart diseases due to the sedentary lifestyle, excessive consumption of alcohol, consumption of junk food, and huge number of diabetic and obese patients. 

To Request a Sample of our Report on US Electroceuticals Market:  https://www.omrglobal.com/request-sample/us-electroceuticals-market

The traumatic brain injury is the most common cause of fatality and disability in the US. As per the report of the Centers for Disease Control and Prevention (CDC), in 2017, 30% of all the injury-related mortalities occurred due to the traumatic brain injury in the US. According to the Center for Medicare and Medicaid Services, in 2017, the US national healthcare expenditure was around $3.5 trillion showing a 3.9% increase in healthcare expenditure. The US has the highest healthcare spending across the globe. In the US, the per capita healthcare expenditure per person in 2017 was around $10,739, as per the CMS. 

 (Get 15% Discount on Buying this Report)

A full Report of US Electroceuticals Market is Available at:  https://www.omrglobal.com/industry-reports/us-electroceuticals-market

US Electroceuticals Market Segmentation

By Product and its Application

·        Cardioverter Defibrillators and Cardiac Pacemaker

·        Arrhythmias

·        Deep Brain Stimulators

·        Parkinson’s Disease

·        Depression

·        Spinal Cord Stimulators

·        Failed Back Syndrome

·        Ischemia

·        Vagus Nerve Stimulators

·        Epilepsy

·        Cochlear Implants

·        Sensorineural Hearing Loss

·        Others (Sacral Nerve Stimulators, Transcutaneous Electrical Nerve Stimulators)

·        Urinary Incontinence

·        Treatment-Resistant Depression

By End-User

·        Hospitals and Clinics

·        Homecare and Other

(This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.)